An open-label, single centre Phase I study of the safety and tolerability of PG545 in patients with advanced solid tumours.

Trial Profile

An open-label, single centre Phase I study of the safety and tolerability of PG545 in patients with advanced solid tumours.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 13 Oct 2017

At a glance

  • Drugs Pixatimod (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 17 Aug 2012 New source identified and integrated (Australian New Zealand Clinical Trials Registry, ACTRN12611000016932).
    • 01 Aug 2012 Status changed from recruiting to discontinued according to a ClinicalTrials.gov record.
    • 20 Sep 2011 According to a Progen Pharmaceuticals media release, company has halted patient recruitment and will formally close the current PG545-101 study once the current cohort of patients is complete.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top